Ferdous Gheyas

Ferdous Gheyas

Auto-generated profile, based on publicly available information

Ferdous Gheyas

Merck & Co., Inc. Rahway New Jersey USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 November 2023 in Clinical and Translational Science
Verified
Journal Article
Open access
MTMaria E Trujillo
Maria E Trujillo
SASurya Ayalasomayajula
Surya Ayalasomayajula
RBRobert O. Blaustein
Robert O. Blaustein
FGFerdous Gheyas
Ferdous Gheyas
Vericiguat, a novel soluble guanylate cyclase (sGC) stimulator, is approved for the treatment of heart failure (HF) with reduced ejection fraction (HFrEF). Decreased nitric oxide (NO) availability, sGC desensitization to NO, sGC deficiency, and reduced cyclic guanosine monophosphate (cGMP) signaling are potential contributing factors for HF disease progression. Vericiguat works via stimulation of sGC in the critical NO‐sGC‐cGMP pathway. Vericiguat is primarily metabolized by glucuronidation via uridine diphosphate‐glucuronosyltransferase (UGT) isoforms UGT1A1 and UGT1A9. Urinary excretion and renal clearance of vericiguat are low. No intrinsic factor had a clinically relevant effect on vericiguat exposure. Vericiguat has low drug–drug interaction potential with no clinically relevant pharmacokinetic or pharmacodynamic interactions observed with warfarin, digoxin, aspirin, or sacubitril/valsartan. The global phase III study VICTORIA included patients with HFrEF who had a recent HF hospitalization or intravenous diuretic treatment for HF. Treatment with vericiguat on top of standard of care resulted in a 10% relative reduction in the primary composite outcome of death from cardiovascular causes or first hospitalization for HF. Vericiguat was well‐tolerated with low incidence of symptomatic hypotension and syncope compared to placebo. Given its positive benefit–risk profile, vericiguat is an important option for high‐risk patients with HFrEF who are already on guideline‐directed medical therapy and had recent worsening of HF. Future efforts to develop additional effective therapies are needed to further reduce morbidity and mortality in patients with HF.

22 March 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
GGGerald R. Galluppi
Gerald R. Galluppi
MAMalidi Ahamadi
Malidi Ahamadi
SBSouvik Bhattacharya
Souvik Bhattacharya
NBNag Budha
Nag Budha
FGFerdous Gheyas
Ferdous Gheyas
JCJack Cook
Jack Cook
A recent industry perspective published in this journal describes the benefits received by drug companies from participation in the MIDD Pilot Program. Along with the primary objectives of supporting good decision‐making in drug development, there were substantial savings in time and development costs. Furthermore, many sponsors reported qualitative benefits such as new learnings and clarity on MIDD strategies and methodology that could be applied to other development programs. Based on the success of the Pilot Program, the FDA recently announced the continuation of the MIDD Paired Meeting Program as part of the Prescription Drug User Fee Act (PDUFA VII). In this report, we describe the collective experiences of industry participants in the MIDD Program to date, including all aspects of the process from meeting request submission to follow‐up actions. The purpose is to provide future participants with information to optimize the value of the MIDD Program.

27 October 2021 in Clinical and Translational Science
Verified
Journal Article
Open access
PDF file
MPMunjal Patel
Munjal Patel
Francesco BellantiFrancesco Bellanti
Francesco Bellanti
NDNaveen M. Daryani
Naveen M. Daryani
NNNadia Noormohamed
Nadia Noormohamed
DHDavid W. Hilbert
David W. Hilbert
MRMatthew L. Rizk
Matthew L. Rizk
In the phase III RESTORE‐IMI 2 study (ClinicalTrials.gov: NCT02493764), the combination antibacterial agent imipenem/cilastatin/relebactam (IMI/REL) demonstrated noninferiority to piperacillin/tazobactam for the end points of all‐cause mortality at day 28 and favorable clinical response at the early follow‐up visit in adult participants with gram‐negative hospital‐acquired bacterial pneumonia/ventilator‐associated bacterial pneumonia (HABP/VABP). Existing population pharmacokinetic models for imipenem (IPM) and REL were updated using data from patients with HABP/VABP from RESTORE‐IMI 2. Creatinine clearance (CrCl), body weight, infection type, and ventilation status were significant covariates in the updated model. The following simulations were performed to calculate the pharmacokinetic/pharmacodynamic joint probability of target attainment among patients with HABP/VABP and varying degrees of renal function: augmented renal clearance (CrCl ≥150 ml/min), normal renal function (CrCl ≥90 to <150 ml/min), renal impairment (mild, CrCl ≥60 to <90 ml/min; moderate, CrCl ≥30 to <60 ml/min; or severe, CrCl ≥15 to <30 ml/min), and end‐stage renal disease (CrCl <15 ml/min). At the recommended IMI/REL dosing regimens across renal categories, greater than 90% of patients in all renal function groups were predicted to achieve joint pharmacokinetic/pharmacodynamic targets at a minimum inhibitory concentration breakpoint of ≤2 μg/ml, regardless of ventilation status. This modeling and simulation analysis supports use of the recommended IMI/REL dosing regimens, adjusted based on renal function, in patients with HABP/VABP.

29 May 2024 in CPT: Pharmacometrics & Systems Pharmacology
Verified
Journal Article
Open access
SASihem Ait-Oudhia
Sihem Ait-Oudhia
DJDavid Jaworowicz
David Jaworowicz
ZHZiheng Hu
Ziheng Hu
SBSébastien Bihorel
Sébastien Bihorel
SHShuai Hu
Shuai Hu
FGFerdous Gheyas
Ferdous Gheyas
Sotatercept is a breakthrough, first‐in‐class biologic, that is FDA‐approved for the treatment of pulmonary arterial hypertension (PAH). A population pharmacokinetic (PopPK) model was developed using data from two phase 1 studies in healthy participants, and two phase 2 studies and one phase 3 study in participants with PAH. The pooled sotatercept PK data encompassed single intravenous (IV) or subcutaneous (SC) doses ranging from 0.01 to 3.0 mg/kg, as well as multiple SC doses ranging from 0.03 to 1.0 mg/kg, with PK samples collected up to a maximum of ~150 weeks following Q3W and Q4W dosing regimens. The final PopPK analysis included 350 participants, with 30 and 320 participants receiving sotatercept IV and SC, respectively. A two‐compartment model with a first‐order absorption rate constant and a linear disposition from central compartment well‐described sotatercept PK. The estimated bioavailability is ~66%; bioavailability, clearance (CL), and central volume (VC) have low to moderate inter‐individual variability. Time‐varying body weight and baseline albumin concentration were statistically significant predictors of PK; CL and VC were predicted to increase with increasing body weight, while CL was predicted to decrease with increasing baseline albumin concentration. However, the magnitude of covariate effects is not predicted to meaningfully alter the disposition of sotatercept. Altogether, the PopPK modeling results demonstrate favorable PK characteristics (low to moderate variability and typical bioavailability), supporting sotatercept as a SC biological agent for the treatment of patients with PAH.

12 December 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
SASihem Ait-Oudhia
Sihem Ait-Oudhia
DJDavid Jaworowicz
David Jaworowicz
ZHZiheng Hu
Ziheng Hu
MGMitali Gaurav
Mitali Gaurav
HBHeather Barcomb
Heather Barcomb
FGFerdous Gheyas
Ferdous Gheyas
Sotatercept is a breakthrough, first‐in‐class biologic, recently approved by the Food and Drug Administration (FDA) for the treatment of pulmonary arterial hypertension (PAH). Exposure‐response (E‐R) analyses and pharmacokinetic/pharmacodynamic (PK/PD) modeling were performed for sotatercept after intravenous and subcutaneous (SC) administrations. Clinical endpoints included 6‐minute walk distance (6MWD), pulmonary vascular resistance (PVR), and probability of N‐terminal pro‐B natriuretic peptide (NT‐proBNP) concentrations < 300 pg/mL for efficacy, and hemoglobin (Hgb) for safety from two Phase 1 studies, two Phase 2 studies, and one Phase 3 study. E‐R models using nonlinear mixed effect modeling approach were developed for 6MWD and PVR, while Cox proportional hazards model and semi‐mechanistic PK/PD model were used for NT‐proBNP and Hgb. Covariate analyses were conducted to identify significant predictors of variability for each of these clinical endpoints. Modeling results showed that increasing sotatercept average concentration (Cavg) at week 24 is associated with increased predicted 6MWD, increased probability of NT‐proBNP concentration < 300 pg/mL, decreased predicted PVR, and increased Hgb which was clinically manageable. All these responses approached their corresponding plateaus at a Cavg range associated with the dose of 0.7 mg/kg Q3W SC. Statistically relevant covariates included age and iron supplementation which slightly increased Hgb‐mediated effect for 6MWD, PAH disease duration, and baseline therapy infusion with prostacyclin for PVR, and WHO functional class for NT‐proBNP. The magnitudes of the impact of these covariates are not clinically meaningful. Taken together, these results support an appropriate benefit–risk profile for the FDA‐approved target dose for sotatercept of 0.7 mg/kg Q3W SC.

27 March 2024 in Clinical Pharmacology & Therapeutics
Verified
Journal Article
Open access
PDF file
MMMohamed‐Eslam F. Mohamed
Mohamed‐Eslam F. Mohamed
SGSandhya Girish
Sandhya Girish
RHRita Humeniuk
Rita Humeniuk
SNSilpa Nuthalapati
Silpa Nuthalapati
ADAmit Desai
Amit Desai
TZTong Zhu
Tong Zhu